RESMED INC RSMDF
OTC · OOTC · stock · Surgical & Medical Instruments & Apparatus
8/9
Piotroski F — financial health
8.65
Altman Z″ — distress risk · safe
22.2%
Dividend payout · safe
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $5.1B | $1.4B | $3.1B | $1.7B | $6.0B |
| 2024 | $4.7B | $1.0B | $2.7B | $1.3B | $4.9B |
| 2023 | $4.2B | $897.6M | $2.4B | $573.6M | $4.1B |
| 2022 | $3.6B | $779.4M | $2.0B | $216.3M | $3.4B |
| 2021 | $3.2B | $474.5M | $1.8B | $634.0M | $2.9B |
| 2020 | $3.0B | $621.7M | $1.7B | $706.9M | $2.5B |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Farrell Michael J. | Chairman and CEO | 2026-06-08 | Option exercise | 4,991 | $146.34 |
| Farrell Michael J. | Chairman and CEO | 2026-06-08 | Sell | 4,991 | $193.96 |
| Rider Michael J | Global General Counsel | 2026-06-01 | Tax withheld | 269 | $190.57 |
| Farrell Michael J. | Chairman and CEO | 2026-05-07 | Option exercise | 4,991 | $146.34 |
| Farrell Michael J. | Chairman and CEO | 2026-05-07 | Sell | 4,991 | $207.82 |
| Farrell Michael J. | Chairman and CEO | 2026-04-07 | Option exercise | 4,991 | $146.34 |
| Farrell Michael J. | Chairman and CEO | 2026-04-07 | Sell | 4,991 | $225.50 |
| Sandercock Brett | Chief Financial Officer | 2026-04-01 | Sell | 1,000 | $224.31 |
Why these scores methodology →
Piotroski F-score: 8/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 8.65 (safe)
- Working capital / assets 0.304
- Retained earnings / assets 0.744
- EBIT / assets 0.206
- Equity / liabilities 2.705
Source: SEC EDGAR filings · CIK 0000943819 · as of 2025-06-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.